Journal of Clinical Endocrinology & Metabolism, Vol 81, 3898-3901, Copyright © 1996 by Endocrine Society

ARTICLES

Structural studies of the thyrotropin receptor and Gs alpha in human thyroid cancers: low prevalence of mutations predicts infrequent involvement in malignant transformation

D Spambalg, N Sharifi, R Elisei, JL Gross, G Medeiros-Neto and JA Fagin
Division of Endocrinology and Metabolism, Cedars-Sinai Medical Center, University of California School of Medicine, Los Angeles 90048, USA.

The genes for either the TSH receptor (TSH-R) or the stimulatory guanine nucleotide-binding protein subunit (Gs alpha) can undergo somatic mutations in thyroid cells, leading to constitutive activation of adenylyl cyclase and the formation of clonal hyperfunctioning thyroid adenomas. Autonomously functioning thyroid adenomas are thought not to be common precursors of thyroid cancer. If this is the case, mutations of the TSH-R or Gs alpha would not be expected to be highly prevalent in thyroid carcinomas. In this paper we report the results of a screen for structural defects in exon 10 of the TSH-R (which includes the whole serpentine structure, but not the extracellular domain) and of Gs alpha in 30 thyroid carcinomas. Five of these were from patients with functioning metastasis, as we hypothesized that if mutations of these genes were to play a role in the progression to malignancy, they would be more likely to manifest in thyroid cancers that retain unusual differentiated function (i.e. capable of synthesizing enough thyroid hormone to render patients euthyroid or hyperthyroid after total thyroidectomy). None of the 30 tumors had activating point mutations of Gs alpha. Only 2 of 30 had somatic mutations of the TSH-R (codon 632: ACC to GCC, Thr to Ala; and ACC to ATC, Thr to Ile, respectively), the latter in a patient with a thyroid hormone-producting follicular carcinoma. These results suggest that events leading to constitutive activation of the adenylate cyclase signal transduction cascade are not a frequent event in the progression toward differentiated thyroid carcinomas.

This article has been cited by other articles:

				J. A. Smith, C.-Y. Fan, C. Zou, D. Bodenner, and M. S. Kokoska Methylation Status of Genes in Papillary Thyroid Carcinoma Arch Otolaryngol Head Neck Surg, October 1, 2007; 133(10): 1006 - 1011. [Abstract] [Full Text] [PDF]

				S G Watson, A D Radford, A Kipar, P Ibarrola, and L Blackwood Somatic mutations of the thyroid-stimulating hormone receptor gene in feline hyperthyroidism: parallels with human hyperthyroidism J. Endocrinol., September 1, 2005; 186(3): 523 - 537. [Abstract] [Full Text] [PDF]

				B. Karges, G. Krause, J. Homoki, K.-M. Debatin, N. de Roux, and W. Karges TSH receptor mutation V509A causes familial hyperthyroidism by release of interhelical constraints between transmembrane helices TMH3 and TMH5 J. Endocrinol., August 1, 2005; 186(2): 377 - 385. [Abstract] [Full Text] [PDF]

				S. J. Marx and W. F. Simonds Hereditary Hormone Excess: Genes, Molecular Pathways, and Syndromes Endocr. Rev., August 1, 2005; 26(5): 615 - 661. [Abstract] [Full Text] [PDF]

				M. Xing, H. Usadel, Y. Cohen, Y. Tokumaru, Z. Guo, W. B. Westra, B. C. Tong, G. Tallini, R. Udelsman, J. A. Califano, et al. Methylation of the Thyroid-stimulating Hormone Receptor Gene in Epithelial Thyroid Tumors: A Marker of Malignancy and a Cause of Gene Silencing Cancer Res., May 1, 2003; 63(9): 2316 - 2321. [Abstract] [Full Text] [PDF]

				C.-R. Chen, G. D. Chazenbalk, S. M. McLachlan, and B. Rapoport Targeted Restoration of Cleavage in a Noncleaving Thyrotropin Receptor Demonstrates that Cleavage Is Insufficient to Enhance Ligand-Independent Activity Endocrinology, April 1, 2003; 144(4): 1324 - 1330. [Abstract] [Full Text] [PDF]

				J. A. Fagin Minireview: Branded from the Start--Distinct Oncogenic Initiating Events May Determine Tumor Fate in the Thyroid Mol. Endocrinol., May 1, 2002; 16(5): 903 - 911. [Abstract] [Full Text] [PDF]

				M. Tonacchera, P. Vitti, P. Agretti, G. Ceccarini, A. Perri, R. Cavaliere, B. Mazzi, A. G. Naccarato, P. Viacava, P. Miccoli, et al. Functioning and Nonfunctioning Thyroid Adenomas Involve Different Molecular Pathogenetic Mechanisms J. Clin. Endocrinol. Metab., November 1, 1999; 84(11): 4155 - 4158. [Abstract] [Full Text]

				M. D. Ringel, M. Saji, W. F. Schwindinger, D. Segev, M. A. Zeiger, and M. A. Levine Absence of Activating Mutations of the Genes Encoding the {alpha}-Subunits of G11 and Gq in Thyroid Neoplasia J. Clin. Endocrinol. Metab., February 1, 1998; 83(2): 554 - 559. [Abstract] [Full Text]

				P. J. Fuller, K. Verity, Y. Shen, P. Mamers, T. Jobling, and H. G. Burger No Evidence of a Role for Mutations or Polymorphisms of the Follicle-Stimulating Hormone Receptor in Ovarian Granulosa Cell Tumors J. Clin. Endocrinol. Metab., January 1, 1998; 83(1): 274 - 279. [Abstract] [Full Text]

				R. Paschke and M. Ludgate The Thyrotropin Receptor in Thyroid Diseases N. Engl. J. Med., December 4, 1997; 337(23): 1675 - 1681. [Full Text] [PDF]

				J. Parma, L. Duprez, J. Van Sande, J. Hermans, P. Rocmans, G. Van Vliet, S. Costagliola, P. Rodien, J. E. Dumont, and G. Vassart Diversity and Prevalence of Somatic Mutations in the Thyrotropin Receptor and Gs{alpha} Genes as a Cause of Toxic Thyroid Adenomas J. Clin. Endocrinol. Metab., August 1, 1997; 82(8): 2695 - 2701. [Abstract] [Full Text] [PDF]